Health Canada warns about use of pain killer Celebrex due to heart risk
“Health Canada has pulled authorization of pain relief drug Celebrex for the treatment of a rare genetic disease, following ‘new information’ linking the drug to an increased risk of heart attack.”
Blogging from Canada continues. The recommended dose for Familial adenomatous polyposis (FAP) – the disease mentioned in the article – is 400 mg twice daily, which the recent data has shown to have an increased risk of cardiac events. The FDA has not made a similar announcement yet.
